The definition of market access ensures that patients can access medicines quickly and continuously, and that they are marketed at a reasonable price that is in line with the drug's effectiveness in treating the disease. The market access strategy is complex, dynamic and constantly evolving. Biopharmaceutical leaders can optimize market access in a product portfolio by analyzing how therapeutic area (AT) dynamics, including level of competition, could influence the use of payment tools to manage access. Over the past few years, payers have increasingly used form tiering as a tool to help control and manage market access.
As public pressure to reduce drug spending intensifies, this trend is likely to continue. However, not all ATs are equally affected. Our analysis of the extent to which competition drives form positioning in eight TAs reveals information on what additional dynamics could be driving form positioning, an indicator of the success of market access strategies. At the beginning of your Market Access career, an entry-level position will generally be with one of the consulting firms specializing in market access as a research or business analyst, moving to senior analyst and then to consultant level.
In younger positions, your time will be divided by the following: About a third of your time will be spent organizing interviews with top opinion leaders (KOL) Payers (the guys who handle the purse and ultimately decide whether or not to refund products and at what level). Almost half of your time will be spent on documentary research, conducting interviews, helping with analysis and developing presentations. The rest of your time will be spent on customer liaison and project management. We can develop your price launch and market access strategy, from developing and adapting your pricing strategy to submitting local HTA or price and rebate dossiers to achieve timely market access for your product.
To cope with this dynamic regulatory environment, pharmaceutical companies have begun to establish the market access function as an integral part of the organization. Remap Consulting is an expert market access consultant with more than 40 years of combined experience in pharmaceutical pricing and reimbursement. Taking note of this, some pharmaceutical companies have begun to establish market access functions (10, 1). In some countries, they are the ones who pay, hold the key to the pharmaceutical market and will continue to exert significant influence.
PRMA Consulting's digital application suite is transforming market access processes for major pharmaceutical and biotech companies. Market access is a broad term used to describe the activities and processes that pharmaceutical and biotech companies carry out to ensure a reimbursed price, which reflects the value of the product to the widest possible patient population in the shortest possible time frame. The pharmaceutical industry has traditionally relied heavily on the push strategy to ensure that its products are successful in the marketplace. Instead, most pharmaceutical companies currently have a divided approach, and market access responsibilities are shared between sales, marketing and regulatory divisions.
In a rapidly evolving landscape, the basics of pricing, reimbursement and time to market remain critically important, but they are no longer sufficient to meet changes in the industry and the broader healthcare market environment. Stagnant developed markets have forced pharmaceutical companies to focus more on emerging markets, which are touted as the next drivers of growth. To gain access to the pharmaceutical market and remain competitive, medical and pharmaceutical technology manufacturers must be able to demonstrate clinical and economic evidence to providers, healthcare decision makers, and payers. Therefore, pharmaceutical and biotech manufacturers need effective market access strategies that allow them to obtain the best possible reimbursement for their assets while keeping those assets accessible to payers, so that patients have access to new and effective therapies as soon as possible.
possible. Therefore, access in emerging markets depends heavily on price, channels, marketing to physicians and government stakeholders. Some private payers are already establishing strategies to reduce the influence of rebates on market access by transferring refunds at the point of sale or creating new types of forms, but it has not yet been seen how this could affect prices and market access. .